These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 26898299

  • 1. Population pharmacokinetics and exposure-response relationship of amatuximab, an anti-mesothelin monoclonal antibody, in patients with malignant pleural mesothelioma and its application in dose selection.
    Gupta A, Hussein Z, Hassan R, Wustner J, Maltzman JD, Wallin BA.
    Cancer Chemother Pharmacol; 2016 Apr; 77(4):733-43. PubMed ID: 26898299
    [Abstract] [Full Text] [Related]

  • 2. Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma.
    Hassan R, Kindler HL, Jahan T, Bazhenova L, Reck M, Thomas A, Pastan I, Parno J, O'Shannessy DJ, Fatato P, Maltzman JD, Wallin BA.
    Clin Cancer Res; 2014 Dec 01; 20(23):5927-36. PubMed ID: 25231400
    [Abstract] [Full Text] [Related]

  • 3. CA125 suppresses amatuximab immune-effector function and elevated serum levels are associated with reduced clinical response in first line mesothelioma patients.
    Nicolaides NC, Schweizer C, Somers EB, Wang W, Fernando S, Ross EN, Grasso L, Hassan R, Kline JB.
    Cancer Biol Ther; 2018 Jul 03; 19(7):622-630. PubMed ID: 29652548
    [Abstract] [Full Text] [Related]

  • 4. Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905).
    Tsao AS, Miao J, Wistuba II, Vogelzang NJ, Heymach JV, Fossella FV, Lu C, Velasco MR, Box-Noriega B, Hueftle JG, Gadgeel S, Redman MW, Gandara DR, Kelly K.
    J Clin Oncol; 2019 Oct 01; 37(28):2537-2547. PubMed ID: 31386610
    [Abstract] [Full Text] [Related]

  • 5. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
    Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V, Rivière F, Janicot H, Gervais R, Locher C, Milleron B, Tran Q, Lebitasy MP, Morin F, Creveuil C, Parienti JJ, Scherpereel A, French Cooperative Thoracic Intergroup (IFCT).
    Lancet; 2016 Apr 02; 387(10026):1405-1414. PubMed ID: 26719230
    [Abstract] [Full Text] [Related]

  • 6. [Systemic Treatment of Malignant Pleural Mesothelioma].
    Nakano T.
    Gan To Kagaku Ryoho; 2017 Dec 02; 44(13):2041-2047. PubMed ID: 29361614
    [Abstract] [Full Text] [Related]

  • 7. Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma.
    Zucali PA, Perrino M, Lorenzi E, Ceresoli GL, De Vincenzo F, Simonelli M, Gianoncelli L, De Sanctis R, Giordano L, Santoro A.
    Lung Cancer; 2014 Jun 02; 84(3):265-70. PubMed ID: 24321581
    [Abstract] [Full Text] [Related]

  • 8. Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in.
    Nowak AK, Lesterhuis WJ, Kok PS, Brown C, Hughes BG, Karikios DJ, John T, Kao SC, Leslie C, Cook AM, Pavlakis N, Briscoe K, O'Byrne KJ, Karapetis CS, Lam WS, Langford A, Yip S, Stockler MR.
    Lancet Oncol; 2020 Sep 02; 21(9):1213-1223. PubMed ID: 32888453
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of phase 1 trials in malignant pleural mesothelioma: description of a series of patients at a single institution.
    Raphael J, Le Teuff G, Hollebecque A, Massard C, Bahleda R, Margery J, Besse B, Soria JC, Planchard D.
    Lung Cancer; 2014 Aug 02; 85(2):251-7. PubMed ID: 24882384
    [Abstract] [Full Text] [Related]

  • 10. Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study.
    van Zandwijk N, Pavlakis N, Kao SC, Linton A, Boyer MJ, Clarke S, Huynh Y, Chrzanowska A, Fulham MJ, Bailey DL, Cooper WA, Kritharides L, Ridley L, Pattison ST, MacDiarmid J, Brahmbhatt H, Reid G.
    Lancet Oncol; 2017 Oct 02; 18(10):1386-1396. PubMed ID: 28870611
    [Abstract] [Full Text] [Related]

  • 11. The efficacy of pemetrexed and bevacizumab intrapleural injection for malignant pleural mesothelioma-mediated malignant pleural effusion.
    Chen D, Li X, Zhao H, Fu Y, Yao F, Hu J, Du N.
    Indian J Cancer; 2014 Mar 02; 51 Suppl 3():e82-5. PubMed ID: 25818740
    [Abstract] [Full Text] [Related]

  • 12. Contemporary Analysis of Prognostic Factors in Patients with Unresectable Malignant Pleural Mesothelioma.
    Billé A, Krug LM, Woo KM, Rusch VW, Zauderer MG.
    J Thorac Oncol; 2016 Feb 02; 11(2):249-55. PubMed ID: 26845118
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Prognosis related clinical and molecular factors in malignant pleural mesothelioma].
    Wang YY, Zhang H, Bai H, Wang SH, Wu MN, An TT, Zhao J, Zhuo ML, Duan JC, Wang ZJ, Wang J.
    Zhonghua Jie He He Hu Xi Za Zhi; 2013 Mar 02; 36(3):162-8. PubMed ID: 23856136
    [Abstract] [Full Text] [Related]

  • 15. Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial.
    Grosso F, Steele N, Novello S, Nowak AK, Popat S, Greillier L, John T, Leighl NB, Reck M, Taylor P, Planchard D, Sørensen JB, Socinski MA, von Wangenheim U, Loembé AB, Barrueco J, Morsli N, Scagliotti G.
    J Clin Oncol; 2017 Nov 01; 35(31):3591-3600. PubMed ID: 28892431
    [Abstract] [Full Text] [Related]

  • 16. Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program.
    Jänne PA, Wozniak AJ, Belani CP, Keohan ML, Ross HJ, Polikoff JA, Mintzer DM, Ye Z, Monberg MJ, Obasaju CK, Pemetrexed expanded access program investigators.
    J Thorac Oncol; 2006 Jul 01; 1(6):506-12. PubMed ID: 17409909
    [Abstract] [Full Text] [Related]

  • 17. Effects of Reduction in Tumor Burden on Survival in Epithelioid Malignant Pleural Mesothelioma.
    Mansfield AS, Peikert T, Vogelzang NJ, Symanowski JT.
    Mayo Clin Proc; 2018 Aug 01; 93(8):1026-1033. PubMed ID: 29804728
    [Abstract] [Full Text] [Related]

  • 18. NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial.
    Gregorc V, Gaafar RM, Favaretto A, Grossi F, Jassem J, Polychronis A, Bidoli P, Tiseo M, Shah R, Taylor P, Novello S, Muzio A, Bearz A, Greillier L, Fontana F, Salini G, Lambiase A, O'Brien M.
    Lancet Oncol; 2018 Jun 01; 19(6):799-811. PubMed ID: 29753703
    [Abstract] [Full Text] [Related]

  • 19. Metabolic response assessment with 18F-FDG-PET/CT is superior to modified RECIST for the evaluation of response to platinum-based doublet chemotherapy in malignant pleural mesothelioma.
    Kanemura S, Kuribayashi K, Funaguchi N, Shibata E, Mikami K, Doi H, Kitajima K, Hasegawa S, Nakano T.
    Eur J Radiol; 2017 Jan 01; 86():92-98. PubMed ID: 28027772
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor Trial.
    Hassan R, Thomas A, Nemunaitis JJ, Patel MR, Bennouna J, Chen FL, Delord JP, Dowlati A, Kochuparambil ST, Taylor MH, Powderly JD, Vaishampayan UN, Verschraegen C, Grote HJ, von Heydebreck A, Chin K, Gulley JL.
    JAMA Oncol; 2019 Mar 01; 5(3):351-357. PubMed ID: 30605211
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.